原发性肺淋巴上皮瘤样癌：应用卡瑞利珠单抗和安罗替尼延长生存时间的 1 例报告。
Primary Pulmonary Lymphoepithelioma-like Carcinoma: A Case Report Utilizing Camrelizumab and Anlotinib for Prolonged Survival.
机构信息
Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, 400030, China.
Pre-Hospital Emergency Department, Chongqing Emergency Medical Center, Chongqing University Central Hospital, Chongqing, China.
出版信息
Anticancer Agents Med Chem. 2024;24(12):954-960. doi: 10.2174/0118715206294031240404071838.
BACKGROUND
Primary Pulmonary Lymphoepithelioma-like Carcinoma (PPLELC) is a rare form of cancer for which no standard treatment has been established to date. Patients with advanced-stage PPLELC generally have a poor prognosis with overall survival of 22.7 months.
CASE PRESENTATION
Here, we report a case of advanced primary pulmonary lymphoepithelioma-like carcinoma. Initially, the patient underwent a first-line (GP) and a second-line (DP) of chemotherapy, which provided temporary relief but resulted in varying degrees of myelosuppression. When the disease progressed again, we administered a third-line treatment consisting of camrelizumab combined with anlotinib.
RESULT
This resulted in a progression-free survival of over 26 months without significant toxic side effects.
CONCLUSION
Our findings suggest that combining camrelizumab and anlotinib could lead to a long progressionfree survival in patients with advanced PPLELC.
背景
原发性肺淋巴上皮瘤样癌（PPLELC）是一种罕见的癌症，目前尚未确立标准治疗方法。晚期 PPLELC 患者的总体生存率为 22.7 个月，预后较差。
病例介绍
本病例报告了一例晚期原发性肺淋巴上皮瘤样癌。患者最初接受一线（GP）和二线（DP）化疗，暂时缓解了病情，但导致不同程度的骨髓抑制。当疾病再次进展时，我们给予三线治疗，包括卡瑞利珠单抗联合安罗替尼。
结果
无明显毒副作用，无进展生存期超过 26 个月。
结论
我们的研究结果表明，卡瑞利珠单抗联合安罗替尼可能使晚期 PPLELC 患者获得较长的无进展生存期。
Zotero 插件